TY  - JOUR
AU  - Afshar-Oromieh, Ali
AU  - Eiber, Matthias
AU  - Fendler, Wolfgang
AU  - Schmidt, Matthias
AU  - Rahbar, Kambiz
AU  - Ahmadzadehfar, Hojjat
AU  - Umutlu, Lale
AU  - Hadaschik, Boris
AU  - Hakenberg, Oliver W
AU  - Fornara, Paolo
AU  - Kurth, Jens
AU  - Neels, O.
AU  - Wester, Hans-Jürgen
AU  - Schwaiger, Markus
AU  - Kopka, Klaus
AU  - Haberkorn, Uwe
AU  - Herrmann, Ken
AU  - Krause, Bernd J
TI  - Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT.[DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055].
JO  - Nuklearmedizin
VL  - 62
IS  - 1
SN  - 0029-5566
CY  - Stuttgart
PB  - Thieme
M1  - DKFZ-2023-00290
SP  - 5 - 19
PY  - 2023
AB  - PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. 68Ga-PSMA-11, 68Ga-PSMA-I</td><td width="150">
AB  - T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.
LB  - PUB:(DE-HGF)16
C6  - pmid:36746147
DO  - DOI:10.1055/a-1984-8167
UR  - https://inrepo02.dkfz.de/record/265695
ER  -